There are times when we honestly wish when predictions we make don’t come true. Sadly that it is not the case when it comes to Senseonics who this morning issued a press release which stated;
“Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system – the Eversense® CGM System – today announced that its Board of Directors has decided to explore potential strategic alternatives to enhance stakeholder value. The Company is engaging Moelis & Company, LLC as its financial advisor and . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.